Study summary · research use only
Effect of delta sleep inducing peptide (DSIP) and arginine vasotocin (AVT) on sleep and motor activity in the rat
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This rat study examined effects of delta sleep inducing peptide (DSIP) and arginine vasotocin (AVT) on sleep and motor activity. Systemic DSIP administration (40-160 nmol/kg i.p.) was not associated with significantly reduced motor activity over 24 h, nor were sleep and EEG delta-band power significantly increased within 2 hours of lateral or third ventricle DSIP infusion (7-24 nmol). Lateral or third ventricle AVT infusion (10(-15)-10(-19) mol) did not enhance sleep or delta-band power. However, dark-time motor activity was reduced 1 and 2 days after 160 nmol/kg DSIP, activity in the first 4 h after 80 nmol/kg was increased, and delta-band power was reduced after third-ventricle DSIP (7 nmol) and AVT (10(-17) mol). The authors concluded neither DSIP nor AVT qualified as a specific sleep-promoting substance in this study.
Abstract
The effect of Delta Sleep Inducing Peptide (DSIP) and arginine vasotocin (AVT) on motor activity and sleep was investigated in the rat. Motor activity was not significantly reduced during the 24 h following systemic DSIP administration (40-160 nmol/kg i.p.), nor were sleep and the power of the EEG delta-band significantly increased in the 2 hours following injection or infusion of DSIP into the lateral or third ventricle (7-24 nmol). Injection or infusion of AVT into the lateral or third ventricle (10(-15)-10(-19) mol) did not enhance sleep and the power of the EEG delta-band. Nevertheless, the following significant effects indicate an unspecified biological action of the peptides: Dark-time motor activity was reduced 1 and 2 days after DSIP administration (160 nmol/kg), and the activity in the first 4 h after injection (80 nmol/kg) was increased. In addition, the power in the delta-band was reduced after administration of DISP (7 nmol) and AVT (10(-17) mol) into the third ventricle. Thus exceedingly small doses of AVT seem to exert not only endocrine, but also electrophysiological effects. It is concluded that neither DSIP nor AVT qualify as a specific sleep-promoting substance.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.